GlassScriptPhysician profile
Michael L Lamb
NPI 1356607196
$3,930.11
in general payments reported to CMS, 2019-2025
34 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $688 · 2023: $531 · 2024: $806 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.65 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $607.17 | 2021-2024 | Biktarvy |
| Merck Sharp & Dohme LLC | $443.20 | 2021-2025 | Zerbaxa, Pifeltro, Dificid |
| Insmed, INC. | $363.09 | 2022-2025 | Arikayce, Brinsupri |
| Averitas Pharma INC. | $339.23 | 2024-2025 | Qutenza |
| Theratechnologies INC. | $309.67 | 2021-2025 | Egrifta, Trogarzo |
| Aimmune Therapeutics, INC. | $264.37 | 2023-2025 | Vowst, Zenpep |
| Viiv Healthcare Company | $181.79 | 2021-2025 | Rukobia, Dovato |
| Smith+Nephew, INC. | $179.52 | 2022-2025 | Collagenase Santyl, Renasys Touch, Regranex |
| Janssen Biotech, INC. | $164.20 | 2021-2023 | Symtuza |
| Abbvie INC. | $133.45 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $116.75 | 2021-2025 | Nuzyra |
| Mimedx Group, INC. | $100.55 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $85.64 | 2021-2022 | |
| Melinta Therapeutics, LLC | $68.74 | 2022-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Bioventus LLC | $54.74 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.44 | 2021-2023 | Cuvitru |
| Reprise Biomedical, INC. | $43.06 | 2025 | Miro3d |
| Medtronic, INC. | $35.81 | 2021 | |
| Integra Lifesciences Corporation | $31.75 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tactile Systems Technology INC | $30.37 | 2025 | Flexitouch Plus, Nimbl |
| Cumberland Pharmaceuticals, INC. | $30.17 | 2025 | Vibativ |
| Acera Surgical, INC. | $28.41 | 2022 | |
| Shionogi INC | $26.42 | 2025 | Fetroja |
| Mayne Pharma Commercial LLC | $24.84 | 2021-2022 | |
| Medline Industries LP | $23.03 | 2021 | |
| Molnlycke Health Care US, LLC | $22.40 | 2025 | Exufiber Ag+, Mextra Superabsorbant, Mepilex Border Flex |
| Convatec INC. | $22.40 | 2025 | |
| Urgo Medical North America, LLC | $20.17 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Cipher Pharmaceuticals US LLC | $19.07 | 2025 | Natroba, Spinosad |
| Hydrofera LLC | $17.71 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2025 | Rebyota |
| Solventum Corporation | $15.47 | 2024 | V.A.C. Dermatac, Activ.A.C. |
| Lifenet Health | $14.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.